OncoMatch/Clinical Trials/NCT06419634
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Is NCT06419634 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including BMS-986497 and Azacitidine for acute myeloid leukemia.
Treatment: BMS-986497 · Azacitidine · Venetoclax — The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Biomarker criteria
Required: CD33 expression (detectable)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: alternative therapies with established benefit
Failed alternative therapies with established benefit
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Yale-New Haven Hospital · New Haven, Connecticut
- Northwestern Memorial Hospital · Chicago, Illinois
- Local Institution - 0007 · Boston, Massachusetts
- Massachusetts General Hospital · Boston, Massachusetts
- Washington University School of Medicine, Siteman Cancer Center · St Louis, Missouri
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06419634 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received alternative therapies with established benefit.
Does this trial require CD33?
Yes, CD33 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify